BioBetter lands funding to relieve cultivated meat’s bottleneck

A funding round led by JVP is poised to reduce cultivated meat production costs by 300% making it more affordable.

Erel Margalit JVP chairman said Biobetter has the key to scale up production of cultivated meat, make it accessible to consumers globally and protect the planet

FoodTech start-up BioBetter, has secured $USD10m in its A –round funding. The round was led by Jerusalem Venture Partners (JVP), with additional investment from Milk and Honey Investments, and the Israeli Innovation Authority (IIA). The injection of capital will be instrumental in accelerating cell-cultured meat closer to its ambitions for broad scale production.

BioBetter harnesses the inherent advantages of tobacco plants as bioreactors for creating the growth factors necessary for the cellular development of cultivated meat. This botanical development could significantly reduce the cost of cultured meat and help rapidly advance its commercialisation, according to the company.

The start-up is on a mission to relieve one of the biggest bottlenecks in this emerging industry: the steep costs and limited availability of growth factors that play a critical role in multiplying cultured meat cells. BioBetter has pioneered a unique protein manufacturing platform for producing growth factors (GFs) using tobacco plants (Nicotiana tabacum) as natural, self-sustaining, animal-free bioreactors.

The field-grown tobacco plants offer a new, sustainable, efficient, and flexible response to the market need for more competitively priced GFs, specifically insulin, transferrin, and FGF2. These compounds are necessary to make cultivated meat commercially viable.

“Biobetter has the key to scale up production of cultivated meat, make it accessible to consumers globally and protect our planet,” declared Erel Margalit, founder & executive chairman of JVP & Margalit Startup City. “This is not only because of the sheer volumes of GFs it can produce but also by virtue of its ability to substantially reduce their cost.”

Growth factors form the key building blocks for cell-cultured proteins. But costs currently run anywhere from $50,000 to $500,000 per gram of FGF2, for example. BioBetter’s technology has the potential to bring these costs down to just one US dollar per gram.

BioBetter will expand to a larger pilot plant within the Tel Hai Industrial Park in the Upper Galilee Region of Israel. The establishment of the new site will substantially increase its tobacco plant-processing capacity, enabling it to meet its current pool of commissions emanating from cell-based meat cultivators globally. The new funding also will be applied to broaden BioBetter’s product portfolio of growth factors. BioBetter currently is recruiting sufficient new talent to double its workforce.

“Biobetter has the potential to create global and regional impact,” enthused Nisan Zeevi, director of JVP and VP of Margalit Startup City Galil. “Closer to home, this venture will create a significant new source of income for local farmers. As cellular agricultural expands, we will dedicate some 500 acres here in the galilee of tobacco plantations to support the industry. This also helps growers find new purpose in the burgeoning alternative protein scene following a reduction in smoking over the last decade that has left many tobacco fields idle and tobacco farmers suffering financial loss.”

“World population growth, combined with dwindling natural resources, are going to put incredible strain on meat supply—and the already fragile environment — in the coming decades,” explains Amit Yaari, PhD, CEO of BioBetter. “Cultivated meat offers a promising solution to these problems and can ensure a more resilient supply chain with better economic and environmental returns.

“Thanks to the Biobetter platform, tobacco is set to make a pivotal comeback as a catalyst for bringing better food security,” added Dana Yarden, MD, co-founder of BioBetter. “As a result of this funding round, we can scale up production in 2023 and expect to go commercial with our tobacco plant-derived, food-grade GF portfolio by 2024.”

Related content